Financings Of The Fortnight: Why Are Royalty-Based Financings On The Rise Again?
This article was originally published in The Pink Sheet Daily
Plus news on recent financings by Vivus, Novira Therapeutics, Theraclone Sciences and Receptos.
You may also be interested in...
FDA approved the oral multiple sclerosis drug March 27 to treat patients with relapsing forms of the disease. Labeling includes data from one trial that showed patients on Tecfidera experienced disability progression less often.
Receptos isn't the only company in the G-coupled protein receptor oral MS drug arena, but it believes its proprietary S1P1 agonist will improve on Novartis' first-in-class S1P1 modulator Gilenya. Unlike Gilenya, which hits four of the five S1P receptor subtypes, the Receptos molecule binds selectively to S1P1 and has a predicted human half-life of approximately one day, potentially improving the safety profile and reducing complications for MS patients.
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.